PharmaCamp_edited.jpg

PharmaCamp 2022:
Personalised Medicine - The Future of Pharma

15-16th September 2022, 
Auditorium, Gertrud-Woker-Strasse 5, 3012 Bern

Compete with other young professionals and students in a pharmaceutical case-challenge. Show your skills to leading pharmaceutical companies in Switzerland and win the award.

Applications until 7th August 2022 at 11:00 AM

ABOUT

Diapositiva1_edited.jpg
 

The premiere edition of PharmaCamp in Bern bridges top young talent and pharmaceutical industry. The goal of the event is to provide the ambitious students, PhDs, PostDocs and recent graduates with an opportunity to showcase their creative problem solving and presentation skills in front the top pharma companies and give them a platform to compete with their peers. On the other hand, the companies will have a perfect opportunity to meet the most perspective young minds and their potential future coworkers/employees. 

The event consists of two parts. First part is open for public, who will have a chance to learn about new trends in pharmaceutical industry by experts from the field of personalised & precision medicine. The following talk session will be aimed at the important considerations when opening and running a biotech startup as well as the approaches of industrial companies to innovation. In the second part of the two-day event, a realistic case-challenge from pharmaceutical industry will be presented and the selected participants (registrations via the Google form in the "Apply now" button) will be divided into balanced groups. The problem solving will require multidisciplinary approach and we therefore encourage people from all natural sciences, engineering as well as business fields to apply. Participants will have time to come up with innovative solutions and prepare a presentation until the next day's afternoon, when they will have a chance to convince the expert panel that their solution is best. The winning team will be awarded with 2'000 CHF (divided between 5 team members) as well as with the eternal glory and fame.

 

1ST DAY SCHEDULE

15th September 2022

REGISTRATION

8:15-9:00

Registration of participants at the auditorium at the Gertrud-Woker-Strasse 5.

TALKS BY EXPERTS - PART 1
(open for public)

9:00-10:45

Greeting by the organisers and partners.

Opening talk session about personalised medicine in pharma industry.

COFFEE BREAK
(open for public)

10:45-11:15

Coffee provided on-site.

TALK BY
EXPERTS - PART 2
(open for public)

11:15-12:15

Continuation of the talk series about considerations when opening a biotech startup and business pitching.

LUNCH BREAK

12:15-13:45

Lunch provided by Swiss Women in Chemistry (SWC) - closed for the case-challenge participants and SWC guests.

BEGINNING OF THE CASE CHALLENGE

13:45-14:30

Presentation of the challenges and division of participants into balanced teams.

WORK IN TEAMS

14:30-18:00

Teams work in separate seminar rooms.

2ND DAY SCHEDULE

16th September 2022

BREAKFAST & COFFEE

8:00-8:30

WORK IN TEAMS

9:00-12:00

LUNCH BREAK

12:00-13:00

Provided at the accomodation.

Teams work in separate seminar rooms on their solutions and finalize their presentations.

Organised lunch.

PRESENTATIONS   OF PROJECTS

13:00-15:00

Teams present in front of the expert panel.

BREAK

15:00-15:30

The participants have time for networking while the panel decides on the winning team.

AWARD PRESENTATION AND APERÒ

15:45-18:00

The panel declares the winning team and the award is presented to the winners. The participants and the companys' representatives have time to network at the aperò.

 

SPEAKERS

Picture1.jpg

Jean-Christophe Leroux is full professor of Drug Formulation and Delivery and head of the Institute of Pharmaceutical Sciences at ETH Zurich, Switzerland. He was trained as pharmacist at the University of Montreal (Canada), obtained his Ph.D. in Pharmaceutical Sciences from the University of Geneva (Switzerland) and worked as postdoctoral fellow at UCSF (USA). Dr. Leroux was professor of Pharmaceutical Technology at the University of Montreal from 1997 to 2008. He has made important fundamental and applied contributions to the fields of biomaterials and drug delivery, and has also been involved in the development of innovative bio-detoxification systems. He is a fellow of the AAPS, EURASC and CRS, and the co-founder of Versantis AG and Inositec AG, two ETH spin-off pharmaceutical companies.

Picture2.jpg

Dr. Mahler is currently CEO and Board Member at ten23 health AG, the human-centric and sustainable pharmaceutical development partner. From 2015 to 2021, Dr. Mahler has been building and leading the Drug Product Services (DPS) Business Unit at Lonza AG. Prior to this, he led Pharmaceutical Development & Supplies at Hoffmann-La Roche (Basel), and built up Formulation R&D for biologics at Roche (2005-2015). From 2000-2005, Dr. Mahler was working at Merck KGaA, Darmstadt, Germany as Principal Formulation Scientist, Lab Manager for Protein Formulation Development and Clinical Trial Manufacturing and CMC Team leader for Erbitux. Dr. Mahler obtained his pharmacy degree and Ph.D. in Toxicology at the University of Meinz as well as Pharmacist specialization degrees in Toxicology & Ecology and Pharmaceutical Technology. He was further trained in Economy and Marketing.  Dr. Mahler obtained his habilitation from the University of Frankfurt in 2010 and is adjunct faculty and lecturer at the universities of Frankfurt, and Basel.

Jean-Christophe Leroux

Hanns-Christian Mahler

Picture1.jpg

From 1999-2004 Sven Rottenberg received a dual education in veterinary pathology (Dipl. ECVP) and molecular biology (PhD) at the University of Bern. In 2004 he joined the group of Piet Borst at the Netherlands Cancer Institute (NKI) in Amsterdam where he became a tenured staff member in 2012. At the NKI he established a new research focus: the study of anti-cancer drug resistance using genetically engineered mouse models of human cancer. In 2014 he returned to the University of Bern as head of the Institute of Animal Pathology. The focus of the Rottenberg group is to understand the underlying mechanisms of resistance to anti-cancer therapies, including both radio- and chemotherapy. His group has identified various mechanisms of PARP inhibitor resistance and thereby generated novel insights into basic mechanisms of the DNA damage response. Moreover, the Rottenberg group has generated unique preclinical models to study residual disease and they have pioneered the use of 3D cancer organoids to study therapy escape.

Sven Rottenberg

Professor of Drug Formulation and Delivery and head of the
Institute of Pharmaceutical Sciences at ETH Zurich, Switzerland.

Chief Enablement Officer (CEO) & Board Member,
ten23 health AG, Basel, Switzerland

Institute of Animal Pathology (Vetsuisse Faculty) and Cancer Therapy Resistance Cluster (DBMR), Bern Center for Precision Medicine, University of Bern, Switzerland

Marieta Duvnjak_photo.jpg

Marieta Duvnjak is Scientific Advisor and Global lead of Innovation Committee in Analytical Research and Development at Novartis, Switzerland. Bringing 10 years of industry experience, she is passionate about science, innovation, supporting and connecting people. Marieta is a subject matter expert for in vitro release method development and in vitro-in vivo (cor)relations for long-acting injectables. Before joining Novartis Technical R&D in 2018, she worked on preclinical and clinical development of value-added oral and long-acting generic products at Teva Pharmaceuticals. Marieta holds a Master’s degree in Drug research and development and PhD in Pharmaceutical sciences.

Marieta Duvnjak

Scientific Advisor and Global lead of Innovation Committee in Analytical Research and Development at Novartis, Switzerland

Pharmacamp_Reber_edited.jpg

Dr Josefine Reber is currently project leader and Lab Head – Molecular Imaging and Radio Ligand Therapy at the Novartis Institutes for BioMedical Research, Switzerland. Before joining Novartis she worked as group leader and study director for toxicology/pharmacology at BSL Bioservice Scientific Laboratories GmbH (Eurofins) in Munich. Josefine holds a Master degree in Biochemistry and Chemical Biology from the University of Berne. 2013 she obtained her PhD in Radiopharmaceutical Sciences from the ETH in Zurich. Before moving to industry, she was a postdoc and later group leader at the HelmholtzZentrum Munich working in multi-disciplinary research associated with the Chair of Biological Imaging at the Technical University of Munich.

Dr Josefine Reber

Project leader and Lab Head, Novartis Institutes for BioMedical Research, Basel, Switzerland

jlr.jpg

Jean-Louis Reymond is a Professor of Chemistry at the University of Bern, Switzerland. He studied Chemistry and Biochemistry at the ETH Zürich and obtained his Ph.D. at the University of Lausanne on natural products synthesis (1989). After a Post-Doc and Assistant Professorship at the Scripps Research Institute, he joined the University of Bern (1997). His current research focuses on chemical space exploration methods combining data science, artificial intelligence, organic synthesis and biological assays to discover new bioactive small molecules and peptides, with applications in membrane transporters modulators, kinase inhibitors, antimicrobials and transfection reagents (https://gdb.unibe.ch). He is the author of > 300 scientific publications and reviews.

https://orcid.org/0000-0003-2724-2942

Jean-Louis Reymond

Professor of Chemistry at the University of Bern, Switzerland

image001_edited.jpg

Stefanie Dobitz is Innovation & Startup Advisor for Health, Medicine, and Life Sciences at the University of Bern and Inselspital, Bern University Hospital. Her focus is on supporting and connecting people for their innovative and successful entrepreneurial journey. Stefanie earned her doctoral thesis from ETH Zurich studying the synthesis and biological evaluation of oligoproline-based peptide ligands for tumor targeting, and holds a CAS in innovation management. Prior joining the University of Bern, Stefanie worked as sales manager for a Swiss CDMO, wherein she supported the pharma and biotech industry in the lead finding of future drug candidates, medical devices, as well as cosmetics.

Stefanie Dobitz

Innovation & Startup Advisor for Health, Medicine, and Life Sciences at the University of Bern and Inselspital

carlita girardin-van der Klaauw.jpg

Carlita Girardin-van der Klaauw, is trained as Medical Doctor at the University of Leiden, the Netherlands and brings 25 years of experience in the Pharmaceutical Industry in leading companies as Pfizer and GSK. She is in GSK responsible for medical affairs in therapeutic areas of Oncology, Vaccines, Specialty (Immunology, allergology) and Respiratory, medical governance, medical information and pharmacovigilance. She is member of Country Management Team in Switzerland. She is passionate about the added value that medical affairs brings to the Healthcare community by sharing science and collaborative projects to close (scientific) gaps to deliver improvements in patient and population health outcomes.

Carlita Girardin-van der Klaauw

Country Medical Director Glaxo Smith Kline, Switzerland

EXPERT PANEL

dr_edited.jpg

Nadine C. Martin is Head of Innovation Management at sitem-insel AG since 2015. Her particular interest goes to Open Innovation in the Life Science sector and she focusses on activities that inspire an innovation culture for all stakeholders to think and act out of the box in order to translate better and faster. She holds an MD and a specialist degrees in Anaesthesiology and in pharmaceutical medicine and a certificate in Innovation Management. She has a long standing experience in pharmaceutical industry and served on boards of professional associations, and as VP on the Board of LIH and now heads the Scientific Council of the FNR, besides being an expert judge and mentor at MassChallenge Switzerland”.

Nadine C. Martin

Head of Innovation Management at sitem-insel AG

toni widmer.jpg

Understanding the needs from a project and merge them together with science is my passion which I discovered during my extramural PhD with the University of Würzburg at Novartis Basel. The Bachelor in Pharmaceutical sciences in combination with a Master in Medicinal Pharmaceutical Sciences at the ETH Zürich was the spark for me to opt for a career in pharmaceutical Industry.

I adore working with scientific matter experts from chemistry, biology, PK sciences and preclinical safety. And I love to balance the project needs with the line function capabilities, challenge the state of the art approach, always striving to get the best for our early development pipeline. This interest continues to my private passion, being it beer brewing, horticulture, DIY projects in and around the house or maintaining our classic 1981 ford capri car.

Toni Widmer

Senior Technical Expert at Novartis, Basel

karmen letonja.png

Karmen Letonja is medical doctor, holding specialist degrees in internal medicine, pulmonology and allergology, with more than 15 years experiences in senior positions in medical affairs in pharmaceuticals. Her roles in recent company GSK has evolved over the time of last 6 years in above the country and local leadership roles, related to different therapeutical areas, last 14 months leading Specialty-Respiratory Medical  Team in Switzerland. Karmen’s primary focus is bringing innovation to the clinical practice through the strengthen scientific differentiation with new data and max out new labels in  cross functional  collaboration.

Karmen Letonja

Head Medical Affairs specialty and respiratory Glaxo Smith Kline, Switzerland

Theresa Visarius_edited_edited.jpg

Theresa Visarius is the Vice President of Business Development at Immunophotonics and Managing Director of the Swiss subsidiary IPS Biopharma AG. She joined the company in 2015 after 8 years as an entrepreneur where she worked with global leaders in health care as well as start-ups to facilitate market access of innovative medical technologies.

At the company, Theresa combines a strong scientific foundation with a passion for game-changing innovation that can lead to impactful patient benefit. Theresa received her PhD in Pharmacology from the University of Bern, Switzerland and holds degrees is biology and chemistry from the USA. She has conducted research in clinical pharmacology, mitochondrial bioenergetics, and molecular toxicology, with a focus on cancer research and clinical pharmacology. 

Theresa Visarius

Vice President of Business Development at Immunophotonics and Managing Director of IPS Biopharma AG

Pharmacamp_Reber_edited.jpg

Dr Josefine Reber is currently project leader and Lab Head – Molecular Imaging and Radio Ligand Therapy at the Novartis Institutes for BioMedical Research, Switzerland. Before joining Novartis she worked as group leader and study director for toxicology/pharmacology at BSL Bioservice Scientific Laboratories GmbH (Eurofins) in Munich. Josefine holds a Master degree in Biochemistry and Chemical Biology from the University of Berne. 2013 she obtained her PhD in Radiopharmaceutical Sciences from the ETH in Zurich. Before moving to industry, she was a postdoc and later group leader at the HelmholtzZentrum Munich working in multi-disciplinary research associated with the Chair of Biological Imaging at the Technical University of Munich.

Dr Josefine Reber

Project leader and Lab Head, Novartis Institutes for BioMedical Research, Basel, Switzerland

pierre mateo.png

Pierre Mateo is a Senior Research Associate at the University of Bern, Switzerland. He studied at the Chemistry and Chemical Engineering School in Lyon (France) and obtained his Ph. D. in organic chemistry at the University of Bern in 2013. After a first Post-Doc in the same field, he joined the Institute of Plant Sciences and integrated the consortium of the Interfaculty Research Cooperation “One Health” as a Research Associate (https://www.onehealth.unibe.ch).
Within this consortium, Dr. Mateo and his colleagues discovered a novel and selective antibiotic against a human pathogen. Dr. Mateo leads the drug development process (MedChem studies). Upon successful pre-clinical assays, the co-inventors will found the pharmaceutical company Enzoxa.

Pierre Mateo

Senior Research Associate at the University of Bern, Switzerland

ORGANISING TEAM

WhatsApp Image 2022-02-26 at 18.16_edited.jpg

When I am not occupied holding a pipette or writing my PhD thesis, I love dedicating my time to work in NGOs and create platforms to bring people together.

https://www.linkedin.com/in/gregorbordon/

Gregor Bordon

Co-founder & Coordinator

JHOAE3430.JPG

PhD student in PharmaTech. Passionate about science, mental health & recycling. Most importantly, I love being around people - learn and connect with each individual and new situation.

https://www.linkedin.com/in/marianna-carone-b61a28196/

Marianna Carone

Co-founder & Coordinator

_DSC9698.jpg

Head of the Innovation Office at the University of Bern. Holds a MA in Modern History and Political Economics from the University of Fribourg, and a Master’s in Public Administration (MPA) from the University of Ottawa, Canada.

https://www.linkedin.com/in/shug1/

Sebastien Hug

Strategic Advisor

despoina.jpg

Postdoctoral researcher at the University of Bern-I have always been fascinated by science, and challenges have always been a boost to learning.

https://www.linkedin.com/in/despo-chatzikleanthous-phd-94773a131/

Despina Chatzikleanthous

Public Relations Manager

giannis.jpg

PhD researcher in Artificial Intelligence in Health and Nutrition. Passionate about travelling, programming, and meeting new people.

https://www.linkedin.com/in/ioannis-papathanail-137942229/

Ioannis Papathanail

IT Manager

photo_william.png

PhD researcher in Enzyme Engineering and Flow Biocatalysis at the University of Bern. When I am not occupied performing enzyme-catalysed reactions, you can find me in the Wallis moutains where I enjoy hiking, bivouacking, ski-touring, climbing, or having a couple of beers with friends.

https://www.linkedin.com/in/lauriane-pillet-a367bb15b/

Laurianne Pillet

Marketing Manager

Zarja Peters_edited.jpg

Zarja Peters is an entrepreneur with an extensive track record in managing performing arts promotion and event management. Her personal signature is the design of tailormade solutions for public and corporate events. She is managing director of Sonus Nobilis art promotion agency acting out of Zug / Switzerland.

https://www.linkedin.com/in/zaria-peters-17a3a2216/

Zarja Peters

Performing Arts Manager

garima_edited.jpg

I am a master's student studying Immunology at the University of Bern. I am greatly interested in medicinal chemistry, drug delivery, and targeting. I am mostly occupied with traveling, sketching, or reading books near Aare in my free time.

Garima Yadav

Volunteer

Anastasia.jpg

Graduated Bachelor of Law in Kiev National University of Trade and Economics. Currently I study International Law as an exchange student at the University of Bern on a master's programme and at the same time prolong my studies in Kiev. During my studies on a bachelor's programme I did some scientific research in a field of Law. I am keen on different interesting topics that have a global meaning, learn foreign languages, read books and travel. 

Anastasiia Haisenok

Volunteer

Camilla Calastra

Marketing Manager

 
 
 

COLLABORATORS

download_edited.png
ub_Logo_english_2019_RGB.png
_PREFERRED USE_GSK_Logo_Full Colour_RGB.png
novartis_logo_pos_rgb (2).jpg
Swiss Young Pharmacists Group.png

SPONSORS